 A. Metastatic breast cancer 7 triple negative, 23 ER after the first 15 patients are enrolled on the non-CCND1cohort; in addition 10 HER2 for combination trastuzumab and PD0332991 therapy up to 55 total enrollment slots B. Metastatic colorectal cancer that harbors the Kras or BRAF mutation 15-30 enrollment slots C. Advanced or metastatic esophageal andor gastric cancer 15-30 enrollment slots D. Cisplatin-refractory, unresectable germ cell tumors 15-30 enrollment slots E. Any tumor type if tissue tests positive for CCND1 amplification, CDK46 mutation, CCND2 amplification OR any other functional alteration at the G1S checkpoint. 15-30 enrollment slots 